Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchSarilumabSarilumab (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group

Hermine et al., European Respiratory Journal, doi:10.1183/13993003.02523-2021, CORIMUNO-SARI-2, NCT04324073
Feb 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 26% Improvement Relative Risk Sarilumab  CORIMUNO-SARI-2  LATE TREATMENT  RCT Is late treatment with sarilumab beneficial for COVID-19? RCT 81 patients in France (March - April 2020) Lower mortality with sarilumab (not stat. sig., p=0.44) c19early.org Hermine et al., European Respiratory J., Feb 2022 Favorssarilumab Favorscontrol 0 0.5 1 1.5 2+
Two open-label RCTs of 97 and 91 critically ill COVID-19 patients in France showing no significant differences with tocilizumab or sarilumab.
risk of death, 26.0% lower, HR 0.74, p = 0.44, treatment 14 of 48 (29.2%), control 13 of 33 (39.4%), NNT 9.8.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hermine et al., 3 Feb 2022, Randomized Controlled Trial, France, peer-reviewed, 6 authors, study period 31 March, 2020 - 20 April, 2020, trial NCT04324073 (history) (CORIMUNO-SARI-2). Contact: ohermine@gmail.com.
This PaperSarilumabAll
Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group
Olivier Hermine, Xavier Mariette, Raphael Porcher, Matthieu Resche-Rigon, Pierre-Louis Tharaux, Philippe Ravaud
doi:10.1183/13993003.02523-2021].
In two prospective randomised studies of COVID-19 patients in the ICU, anti-IL-6 receptor did not significantly increase early survival without mechanical ventilation. However, due to the small number of patients, no definitive conclusion could be drawn. https://bit.ly/
Secondary outcomes Overall survival (%) Estimate at day 14 90 (82-99) 79 (68-92) HR 0.37 (0.12-1. Author contributions: All authors made substantial contributions to the conception and design or acquisition, analysis or interpretation of the data, and the drafting or critical revision of the manuscript. All authors had full access to the data and take responsibility for the integrity of the work. Approval to submit the manuscript for publication was made by all authors. Conflict of interest: P-L. Tharaux has received honoraria for participation on advisory boards for Travere therapeutics. All other author disclose no potential conflicts of interest related to this work. Support statement: This trial was publicly funded (Ministry of Health, Programme Hospitalier de Recherche Clinique (PHRC COVID-19-20-0143, PHRC COVID-19-20-0029), Foundation for Medical Research (FRM), AP-HP Foundation and the Reacting programme). Funders had no access to the trial data and had no role in the design, conduct or reporting of the trial. Roche and Sanofi donated TCZ and SARI in unrestricted grants, respectively, and had no role in the trial design or conduct; the collection, management, analysis or interpretation of the data; or in the preparation, review of the manuscript or the approval of the manuscript for submission. Funding information for this article has been deposited with the Crossref Funder Registry.
References
Chen, Zhou, Dong, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet
Dechartres, Trinquart, Boutron, Influence of trial sample size on treatment effect estimates: meta-epidemiological study, BMJ, doi:10.1183/13993003.02523-2021
Grifoni, Valoriani, Cei, Interleukin-6 as prognosticator in patients with COVID-19, J Infect
Guan, Ni, Hu, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med
Gupta, Wang, Hayek, Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19, JAMA Intern Med
Hermine, Tharaux, Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial, JAMA Intern Med
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Investigators, Interleukin-6 receptor antagonists in critically ill patients with Covid-19, N Engl J Med
Lescure, Honda, Fowler, Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Respir Med
Mariette, Hermine, Tharaux, Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): an open-label randomised controlled trial, Lancet Rheumatol, doi:10.1183/13993003.02523-202111
Merad, Subramanian, Wang, An aberrant inflammatory response in severe COVID-19, Cell Host Microbe
Placais, Richer, Noël, Immune intervention in COVID-19: a matter of time?, Mucosal Immunol
Relton, Torgerson, 'cathain, Rethinking pragmatic randomised controlled trials: introducing the "cohort multiple randomised controlled trial" design, BMJ
The, Group, Dexamethasone in hospitalized patients with Covid-19, N Engl J Med
Valle, Kim-Schulze, Huang, An inflammatory cytokine signature predicts COVID-19 severity and survival, Nat Med
Wu, Liu, Zhao, Clinical characteristics of imported cases of coronavirus disease 2019 (COVID-19) in Jiangsu province: a multicenter descriptive study, Clin Infect Dis
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Zhu, Pang, Ji, Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis, J Med Virol
{ 'indexed': {'date-parts': [[2024, 8, 25]], 'date-time': '2024-08-25T04:30:58Z', 'timestamp': 1724560258256}, 'reference-count': 22, 'publisher': 'European Respiratory Society (ERS)', 'issue': '2', 'license': [ { 'start': { 'date-parts': [[2022, 2, 3]], 'date-time': '2022-02-03T00:00:00Z', 'timestamp': 1643846400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc/4.0/'}], 'funder': [ {'name': 'PHRC COVID', 'award': ['PHRC COVID-19-20-0143, PHRC COVID-19-20-0029']}, { 'DOI': '10.13039/501100002915', 'name': 'Fondation pour la Recherche Médicale', 'doi-asserted-by': 'publisher', 'id': [{'id': '10.13039/501100002915', 'id-type': 'DOI', 'asserted-by': 'publisher'}]}], 'content-domain': {'domain': ['ersjournals.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2022, 8]]}, 'abstract': '<jats:sec><jats:title>Background</jats:title><jats:p>Our objective was to determine whether ' 'anti-interleukin (IL)-6 receptors improve outcomes of critically ill patients with ' 'coronavirus disease 2019 (COVID-19) pneumonia. We report on two cohort-embedded, ' 'investigator-initiated, multicentre, open-label, Bayesian randomised controlled clinical ' 'trials.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Patients were ' 'randomly assigned to receive either usual care (UC) or UC+tocilizumab (TCZ) 8\u2005' 'mg·kg<jats:sup>−1</jats:sup> (TOCI-2 trial) or UC or UC+sarilumab (SARI) 200\u2005mg (SARI-2 ' 'trial), both intravenously on day 1 and, if clinically indicated, on day ' '3.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Between 31 March and ' '20 April 2020, 97 patients were randomised in the TOCI-2 trial, to receive UC (n=46) or ' 'UC+TCZ (n=51). At day 14, numbers of patients who did not need noninvasive ventilation (NIV) ' 'or mechanical ventilation (MV) and were alive with TCZ or UC were similar (47% ' '<jats:italic>versus</jats:italic> 42%; median posterior hazard ratio (HR) 1.19, 90% credible ' 'interval (CrI) 0.71–2.04), with a posterior probability of HR &gt;1 of 71.4%. Between 27 ' 'March and 4 April 2020, 91 patients were randomised in the SARI-2 trial, to receive UC (n=41) ' 'or UC+SARI (n=50). At day 14, numbers of patients who did not need NIV or MV and were alive ' 'with SARI or UC were similar (38% <jats:italic>versus</jats:italic> 33%; median posterior HR ' '1.05, 90% CrI 0.55–2.07), with a posterior probability of HR &gt;1 of 54.9%. Overall, the ' 'risk of death up to day 90 was: UC+TCZ 24% <jats:italic>versus</jats:italic> UC 30% (HR 0.67, ' '95% CI 0.30–1.49) and UC+SARI 29% <jats:italic>versus</jats:italic> UC 39% (HR 0.74, 95% CI ' '0.35–1.58). Both TCZ and SARI increased serious infectious ' 'events.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>In critically ' 'ill patients with COVID-19, anti-IL-6 receptors did not significantly increase the number of ' 'patients alive without any NIV or MV by day 14.</jats:p></jats:sec>', 'DOI': '10.1183/13993003.02523-2021', 'type': 'journal-article', 'created': {'date-parts': [[2022, 2, 3]], 'date-time': '2022-02-03T17:28:15Z', 'timestamp': 1643909295000}, 'page': '2102523', 'update-policy': 'http://dx.doi.org/10.1183/ers-crossmark-policy', 'source': 'Crossref', 'is-referenced-by-count': 31, 'title': 'Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 ' 'pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group', 'prefix': '10.1183', 'volume': '60', 'author': [ {'given': 'Olivier', 'family': 'Hermine', 'sequence': 'first', 'affiliation': []}, {'given': 'Xavier', 'family': 'Mariette', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-5277-4679', 'authenticated-orcid': False, 'given': 'Raphael', 'family': 'Porcher', 'sequence': 'additional', 'affiliation': []}, {'given': 'Matthieu', 'family': 'Resche-Rigon', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-6062-5905', 'authenticated-orcid': False, 'given': 'Pierre-Louis', 'family': 'Tharaux', 'sequence': 'additional', 'affiliation': []}, {'given': 'Philippe', 'family': 'Ravaud', 'sequence': 'additional', 'affiliation': []}], 'member': '81', 'published-online': {'date-parts': [[2022, 2, 3]]}, 'reference': [ { 'key': '2022081002250540000_60.2.2102523.1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciaa199'}, { 'key': '2022081002250540000_60.2.2102523.2', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)30183-5'}, { 'key': '2022081002250540000_60.2.2102523.3', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)30211-7'}, { 'key': '2022081002250540000_60.2.2102523.4', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2002032'}, { 'key': '2022081002250540000_60.2.2102523.5', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)30566-3'}, { 'key': '2022081002250540000_60.2.2102523.6', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2021436'}, { 'key': '2022081002250540000_60.2.2102523.7', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.chom.2021.06.018'}, { 'key': '2022081002250540000_60.2.2102523.8', 'doi-asserted-by': 'crossref', 'first-page': '35', 'DOI': '10.1002/jmv.26085', 'article-title': 'Elevated interleukin-6 is associated with severity of COVID-19: a ' 'meta-analysis', 'volume': '93', 'author': 'Zhu', 'year': '2020', 'journal-title': 'J Med Virol'}, { 'key': '2022081002250540000_60.2.2102523.9', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/S41591-020-1051-9'}, { 'key': '2022081002250540000_60.2.2102523.10', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jinf.2020.06.001'}, { 'key': '2022081002250540000_60.2.2102523.11', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41385-021-00464-w'}, { 'key': '2022081002250540000_60.2.2102523.12', 'doi-asserted-by': 'crossref', 'first-page': '32', 'DOI': '10.1001/jamainternmed.2020.6820', 'article-title': 'Effect of tocilizumab vs usual care in adults hospitalized with ' 'COVID-19 and moderate or severe pneumonia: a randomized clinical trial', 'volume': '181', 'author': 'Hermine', 'year': '2021', 'journal-title': 'JAMA Intern Med'}, { 'key': '2022081002250540000_60.2.2102523.13', 'doi-asserted-by': 'crossref', 'first-page': '1241', 'DOI': '10.1001/jamainternmed.2021.2209', 'article-title': 'Effectiveness of tocilizumab in patients hospitalized with COVID-19: a ' 'follow-up of the CORIMUNO-TOCI-1 randomized clinical trial', 'volume': '181', 'author': 'Mariette', 'year': '2021', 'journal-title': 'JAMA Intern Med'}, { 'key': '2022081002250540000_60.2.2102523.14', 'doi-asserted-by': 'crossref', 'first-page': 'e24', 'DOI': '10.1016/S2665-9913(21)00315-5', 'article-title': 'Sarilumab in adults hospitalised with moderate-to-severe COVID-19 ' 'pneumonia (CORIMUNO-SARI-1): an open-label randomised controlled trial', 'volume': '4', 'year': '2022', 'journal-title': 'Lancet Rheumatol'}, { 'key': '2022081002250540000_60.2.2102523.15', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.c1066'}, { 'key': '2022081002250540000_60.2.2102523.16', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S1473-3099(20)30483-7'}, { 'key': '2022081002250540000_60.2.2102523.17', 'doi-asserted-by': 'crossref', 'first-page': '41', 'DOI': '10.1001/jamainternmed.2020.6252', 'article-title': 'Association between early treatment with tocilizumab and mortality ' 'among critically ill patients with COVID-19', 'volume': '181', 'author': 'Gupta', 'year': '2021', 'journal-title': 'JAMA Intern Med'}, { 'key': '2022081002250540000_60.2.2102523.18', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2021.11330'}, { 'key': '2022081002250540000_60.2.2102523.19', 'doi-asserted-by': 'crossref', 'first-page': '522', 'DOI': '10.1016/S2213-2600(21)00099-0', 'article-title': 'Sarilumab in patients admitted to hospital with severe or critical ' 'COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial', 'volume': '9', 'author': 'Lescure', 'year': '2021', 'journal-title': 'Lancet Respir Med'}, { 'key': '2022081002250540000_60.2.2102523.20', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2100433'}, { 'key': '2022081002250540000_60.2.2102523.21', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(21)00676-0'}, { 'key': '2022081002250540000_60.2.2102523.22', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.f2304'}], 'container-title': 'European Respiratory Journal', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1183/13993003.02523-2021', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 8, 10]], 'date-time': '2022-08-10T09:25:20Z', 'timestamp': 1660123520000}, 'score': 1, 'resource': {'primary': {'URL': 'http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02523-2021'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 2, 3]]}, 'references-count': 22, 'journal-issue': { 'issue': '2', 'published-online': {'date-parts': [[2022, 8, 10]]}, 'published-print': {'date-parts': [[2022, 8]]}}, 'alternative-id': ['10.1183/13993003.02523-2021'], 'URL': 'http://dx.doi.org/10.1183/13993003.02523-2021', 'relation': {}, 'ISSN': ['0903-1936', '1399-3003'], 'subject': [], 'container-title-short': 'Eur Respir J', 'published': {'date-parts': [[2022, 2, 3]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit